GlassScriptPhysician profile
Danielle Oliveira
NPI 1730882762
$2,536.27
in general payments reported to CMS, 2019-2025
28 companies · $121 in 2025
The $121 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $732 · 2024: $1,684 · 2025: $121.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,417 · Education: $119.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,417.03 |
| Education | $119.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $652.04 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $213.97 | 2023-2024 | Entyvio, Eohilia, Trintellix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $187.28 | 2024-2025 | Xifaxan, Trulance |
| Celgene Corporation | $155.97 | 2024 | Zeposia |
| Novo Nordisk INC | $154.95 | 2023 | Rybelsus, Ozempic, Wegovy |
| Gilead Sciences, INC. | $142.30 | 2024 | |
| Phathom Pharmaceuticals, INC. | $136.33 | 2024 | Voquezna |
| Ardelyx, INC. | $104.33 | 2024 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $99.33 | 2024 | Dupixent |
| Lilly USA, LLC | $95.12 | 2023-2024 | Omvoh, Jardiance, Mounjaro |
| Janssen Biotech, INC. | $84.99 | 2024 | Stelara |
| Ironwood Pharmaceuticals, INC | $59.72 | 2024 | |
| Glaxosmithkline, LLC. | $58.92 | 2023-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Qol Medical, LLC | $58.04 | 2024 | Sucraid |
| Genzyme Corporation | $47.74 | 2024 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celltrion USA INC. | $34.25 | 2024 | Zymfentra |
| Sumitomo Pharma America, INC. | $28.82 | 2023 | Gemtesa |
| Intercept Pharmaceuticals, INC. | $24.50 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $23.77 | 2023 | Breztri |
| Exact Sciences Corporation | $23.53 | 2023 | Cologuard Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $23.52 | 2023 | |
| Indivior INC. | $23.28 | 2023 | Sublocade |
| Idorsia Pharmaceuticals US INC | $19.35 | 2023 | Quviviq |
| Ferring Pharmaceuticals INC. | $18.84 | 2024 | Rebyota |
| Teva Pharmaceuticals USA, INC. | $18.40 | 2023 | Austedo Xr |
| Kowa Pharmaceuticals America, INC. | $16.56 | 2023 | Seglentis, Livalo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.13 | 2023 | |
| Evoke Pharma, INC. | $14.29 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Oliveira listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.